bero@medicine.ucsf.edu
(415) 476-1067 (voice)
(415) 502-0792 (fax)

Box 0613, UCSF; San Francisco, CA 94143-0613

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)

Bero LA., Galbraith A., & Rennie D. The publication of sponsored symposiums in medical journals. New England Journal of Medicine, 1992 ; 327 : 1135-1140.

Cho MK., & Bero LA. Instruments for assessing the quality of drug studies published in the Medical Literature. JAMA, 1994; 272: 101-104.

Cho M., & Bero L. The quality of drug articles published in symposium proceedings. Annals of Internal Medicine, 1996 ; 124 : 485-489.

Bero LA., Glantz SA., & Rennie D. Publication bias and public health policy on environmental tobacco smoke. Journal of the American Medical Association, 1994; 272: 133-136

Stryer D., & Bero L. Characteristics of materials distributed by drug companies. Journal of General Internal Medicine, 1996; 11: 575-583.

Bero LA., & Rennie D. Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care, 1996; 12 (2): 209-237.

Barnes D., & Bero L. Scientific quality of original research articles on environmental tobacco smoke. Tobacco Control, 1997; 6: 19-26.

Misakian S., & Bero L. Publication bias and research on passive smoking. Journal of the American Medical Association, 1998; 280 (13): 250-253.

Barnes D., & Bero L. Why review articles on the health effects of passive smoking reach different conclusions. Journal of the American Medical Association, 1998; 279: 1566-1570.

Bero L., Grilli R., Grimshaw J., Harvey E., Oxman AD., & Thomson MA on behalf of the Cochrane Effective Pratcice and Organization of Care Group. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. British Medical Journal, 1998; 317: 465-468.

Bero L., & Jadad A. How patients and policy makers can use systematic reviews for decision-making. Annals of Internal Medicine, 1997; 127: 37-42.

Kennedy G., & Bero L. Print media coverage of research on passive smoking. Tobacco Control, 1999; 8: 254-260.

Bero LA., Mays NB., Barjesteh K., & Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes (Cochrane Review). In: The Cochrane Library, 1999; Issue 2. Oxford: Update Software (first published in 1995).

Boyd E., & Bero L. Assessing faculty financial relationships with industry: A case study. JAMA, 2000; 284: 2209-2214.

Bero LA., Montini T., Bryan-Jones K., & Mangurian C. Science in regulatory policy making: Case studies in the development of workplace smoking restrictions. Tobacco Control, 2001; 10: 329-336.

Hong M., & Bero L. How the industry responded to an influential study on the health effects of secondhand smoke. BMJ, 2002; 325: 1413-1416.

Montini T., Mangurian C., & Bero L. Assessing the evidence submitted in the development of a workplace smoking regulation: The case of Maryland. Public Health Reports, 2002; 117: 291-298.

Shamasunder B., & Bero L. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. JAMA, 2002; 288: 738-744.

Lee K., Schotland M., Bacchetti P., & Bero L. Association of journal quality indicators with methodological quality of clinical research articles. JAMA, 2002; 287: 2805-2808.

G Mowatt, L Shirran, J Grimshaw, D Rennie, A Flanagin, V Yank, G MacLennan, P Gotzsche, and L Bero. Prevalence of honorary and ghost authorship in Cochrane reviews. Journal of the American Medical Association, 2002; 287: 2769-2771.

R Malone, L Wenger, and L Bero. High school journalistsÕ perspectives on tobacco. Journal of Health Communication, 2002 7:139-156.

Schotland M., & Bero L. Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. Risk Analysis, 2002; 22: 131-140.

Boyd EA, Cho MK, & Bero LA. Financial conflict-of-interest policies in clinical research: Issues for clinical investigators. Academic Medicine, 2003; 78: 769-774.

Lexchin J, Bero L, Djulbegovic B, & Bero L. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ, 2003; 326: 1167-1170.

Roth A, Dunsby J, & Bero L. Framing processes in public commentary on U.S. federal tobacco control regulation. Social Studies of Science, 2003; 33: 7-44.

Bero L. Implications of the tobacco industry documents for public health and policy. Annu.Rev. Public Health, 2003; 24: 267-288.

Bryan-Jones, & Bero L. Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. AJPH, 2003; 93: 585-592.

Boyd, E., Lipton, S., Bero, L. Implementation of financial disclosure policies to manage conflicts of interest. Health Affairs, 2004; 23: 206-214.

Lipton S., Boyd., E & Bero, LA. Conflicts of interest in research: Policies, processes and attitudes. Accountability in Research, 2004; 11: 83-102.

White J., & Bero, L. Public health under attack: The American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. American Journal of Public Health, 2004; 94: 240-250.

Dunsby, J., Bero, L. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes. Tobacco Control, 2004; 13: 362-369.

Bero, L. Tobacco industry manipulation of research. Public Health Reports, 2005; 120: 200-208.

Bero, L. Glantz, S. Hong, M. The limits of competing interest disclosures. Tobacco Control, 2005; 14: 118-126.

Cook, D., Tong, E., Glantz, S., & Bero, L. The power of paperwork: How Philip Morris neutralized the medical code for second hand smoke. Health Affairs, 2005; 24: 994-1004.

Baba, A., Cook, D., McGarity, T., & Bero, L. Legislating ÒSound ScienceÓ: Role of the tobacco industry. American Journal of Public Health, 2005; 95: S20-S27.

Glaser, BE., & Bero, L. Attitudes of academic and clinical researchers toward financial ties in research: A systematic review. Science and Engineering Ethics, 2005; 11: 553-573.

Hong, M-K and Bero, L. Tobacco industry sponsorship of a book and conflict of interest. Addiction, 2006; 101: 1202-1211.

Lee, K., Boyd, E., Holroyd-Leduc, J., Bacchetti, P., and Bero, L. Predictors of publication: Characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Medical Journal of Australia, 2006; 184: 621-626.

Hong, M-K., and Bero, L. Tobacco industry sponsorship of a book and conflict of interest. Addiction, 2006; 101: 1202-11.

Steinman, MA., Bero, LA., Chren, M-M., and Landefeld, S. Narrative review: The promotion of Gabapentin: An analysis of internal industry documents. Annals of Internal Medicine, 2006; 145: 284-293.

Lopipero, P., and Bero, L. Tobacco interests or the public interest: Twenty years of industry strategies to undermine airline smoking restrictions. Tobacco Control, 2006; 15: 323-332.

Brol, LA. Evaluating systematic reviews and meta-analyses. Journal of Law & Policy, 2006; 14: 569-593.

Nguyen, NT., Cook, DM., & Bero, LA. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the counter status: A comparative case study. Clinical Therapeutics, 2006; 28: 1231-1243.

Cook, D., and Bero, L. Identifying carcinogens: The tobacco industry and regulatory politics in the United States. Int J of Health Services, 2006; 36: 747-766.

12/11/06